Patent details

Basic Information

Publication number:

EP3326616

PCT Application Number:

Type:

European Patent Granted for LU

Legal Status:

Lapsed

Application number:

EP172021172

PCT Publication Number:

First applicant's nationality:

Translation Language:

EPO Publication Language:

English

English Title of Invention:

LIPOSOMAL MITIGATION OF DRUG-INDUCED LONG QT SYNDROME AND POTASSIUM DELAYED-RECTIFIER CURRENT

French Title of Invention:

ATTÉNUATION LIPOSOMALE DU SYNDROME DU QT LONG INDUIT PAR UN MÉDICAMENT ET DU COURANT DE POTASSIUM À REDRESSEMENT RETARDÉ

German Title of Invention:

LIPOSOMALE ABSCHWÄCHUNG DES ARZNEIMITTELINDUZIERTEN LONG-QT-SYNDROMS MITTELS STROM AUS EINEM DURCH KALIUM VERZÖGERTEN UMRICHTER

SPC Number:

Dates

Filing date:

03/06/2012

Grant date:

28/07/2021

EP Publication Date:

30/05/2018

PCT Publication Date:

Claims Translation Received Date:

Translations Received Date (B1 EP Publication):

Translations Received Date (B2 EP Publication):

Translations Received Date (B3 EP Publication):

Publication date:

28/07/2021

EP B1 Publication Date:

28/07/2021

EP B2 Publication Date:

EP B3 Publication Date:

Lapsed date:

03/06/2022

Expiration date:

03/06/2032

Renunciation date:

Revocation date:

Annulment date:

Owner

From:

21/07/2021

 

 

Name:

Signpath Pharma Inc.

Address:

9710 Ruskin Circle, Sandy, UT 84092, United States (US)

Inventor

Name:

HELSON, Lawrence

Address:

United States (US)

Priority

Priority Number:

201161493257 P

Priority Date:

03/06/2011

Priority Country:

United States (US)

Classification

IPC classification:

A61K 9/127; A61P 9/00; A61P 9/04; A61K 31/12; A61K 31/445; A61K 31/18;

Publication

European Patent Bulletin

Issue number:

202130

Publication date:

28/07/2021

Description:

Grant (B1)

Annual Fees

Annual Fee Due Date:

Annual Fee Number:

Expected Payer:

Last Annual Fee Payment Date:

Last Annual Fee Paid Number:

Payer:

Filing date	Document type	Number of pages